£1bn London Cancer Hub extension gets go-ahead amid UK life sciences push
The London Cancer Hub, a key centre for the UK’s oncology research output, is undergoing a major expansion to increase…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
Eisai signs $388m deal for Japanese rights to Henlius’ anti-PD-1 mAb
Japanese pharmaceutical giant Eisai has forged an oncology licensing deal worth up to $388m with Shanghai Henlius Biotech. Through this…
-
GSK’s oncology and HIV drugs drive 7% sales rise in 2025
GSK has posted positive sales results for fiscal year 2025 (FY2025) as the company’s new CEO, Luke Miels, takes the…
-
Pfizer sets sights on R&D strategy amid modest FY25 results
New York-based pharma giant Pfizer has met targets for its fiscal year 2025 (FY25) financials, which come as the company…
-
Amgen hands back eczema drug to Kyowa Kirin despite positive late-stage data
Amgen is handing back the rights of its successful in-licensed atopic dermatitis (AD) asset, rocatinlimab, to Kyowa Kirin. In a…
-
Sanofi touts strong new launch sales amid looming Dupixent patent expiry
Sanofi is making successful strides to restock its pipeline and shore up revenue streams amid the looming patent expiry of…
-
AstraZeneca pours $15bn into Chinese R&D and manufacturing operations
Pharma giant AstraZeneca is pledging $15bn to fund an R&D and manufacturing capacity expansion in China – marking a significant…
-
NICE greenlights Pfizer’s Talzenna for NHS use
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Talzenna (talazoparib) in a step forward for…
-
High-dose biologic delivery to become industry standard
As the pharmaceutical industry progresses further into the age of personalised medicine, next-generation, targeted and disease-modifying biologics are becoming increasingly…
-
BMS bets on Janux’s novel solid tumour therapy through $850m deal
Bristol Myers Squibb (BMS) has added to its oncology pipeline through an exclusive global licensing agreement with Janux Therapeutics. This…